Zentynel

Zentynel is the first venture capital fund specializing in biotechnology in Latin America. Founded through the convergence of Fundación Ciencia & Vida and Venturance Alternative Assets, Zentynel combines capital, scientific depth, and operational experience to help founders transform innovative science into scalable businesses. They invest across the biotechnology value chain, shaping global biotechnology with a One Health perspective, recognizing the interconnection between human, animal, and environmental health. Their investment approach prioritizes impact alongside financial returns, measuring it at global, social, and individual levels. Zentynel's investment thesis centers on supporting audacious Latin American entrepreneurs. They seek to invest in and develop technologies that address critical needs and generate measurable positive change. The "Una Salud" (One Health) perspective is integral to their investment decisions, ensuring that potential investments consider the interconnectedness of health across different domains. Impact measurement is a key component of their investment strategy, considered as fundamental rather than secondary. Zentynel aims to measure the global, social, and individual impact of their investments, demonstrating a commitment to generating value beyond financial returns. They aim to translate innovative science into real-world impact by funding and supporting Latin American entrepreneurs in the biotechnology sector. Overall, Zentynel’s strategy involves actively supporting portfolio companies by using a deep understanding of both the biotech landscape and the Latin American entrepreneurial ecosystem. They are able to provide not only capital but also operational guidance and access to a valuable network.

Biotechnology, One Health (human, animal, and environmental health)

Core thematic spaces, technologies, and target market segments of interest.